Arch Therapeutics, Inc. (ARTH)
Stock Price:
$0.170 USD
0.001 (0.59%)
Updated Aug 6, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
32.82M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-4.12M |
| Shares Out |
193.04M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
10.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$0.170 |
| Previous Close |
$0.169 |
| Change ($) |
0.001 |
| Change (%) |
0.59% |
| Day's Open |
0.169 |
| Day's Range |
0.165 - 0.169 |
| Day's Volume |
281,595 |
| 52-Week Range |
0.121 - 0.310 |
More Stats
| Market Cap |
32.82M |
| Enterprise Value |
31.53M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
193.04M |
| Float |
153.05M |
| EPS (basic) |
-0.03 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.21 |
| PE Ratio |
n/a |
| Forward PE |
10.75 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
-5.54M |
| Net Income |
-4.12M |
| Free Cash Flow |
-4.97M |
| Net Cash |
1.29M |
| Net Cash / Share |
0.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-99.54% |
| ROE |
-1,646.09% |
| ROIC |
-1,076.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$1.38*
(711.76% upside)
Low
1.25
Current: $0.170
High
1.50
Target: 1.38
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -6.37 | -7.45 | -7.30 | -6.05 | -5.46 | -4.61 | -1.74 | -0.42 | -0.01 |
| Net Income | -4.55 | -4.81 | -7.79 | -5.99 | -2.95 | -8.14 | -1.85 | -0.58 | -0.01 |
| Shares Outstanding | 166 | 153 | 143 | 121 | 81.39 | 67.49 | 21.37 | 5.65 | 1.07 |
| Earnings Per Share | -0.03 | -0.03 | -0.05 | -0.05 | -0.04 | -0.12 | -0.09 | -0.10 | - |
| Operating Cash Flow | -5.27 | -5.91 | -5.62 | -4.75 | -4.24 | -3.35 | -1.43 | -0.25 | - |
| Capital Expenditures | - | -0.02 | -0.01 | - | - | - | - | - | - |
| Free Cash Flow | -5.27 | -5.93 | -5.62 | -4.75 | -4.24 | -3.35 | -1.43 | -0.25 | - |
| Cash & Equivalents | 2.18 | 4.67 | 5.99 | 5.04 | 3.96 | 0.83 | 1.56 | 0.02 | 0.02 |
| Total Debt | - | - | - | 0.98 | 1.44 | 0.96 | 0.94 | 2.01 | - |
| Net Cash / Debt | 2.18 | 4.67 | 5.99 | 4.06 | 2.52 | -0.12 | 0.61 | -1.99 | 0.02 |
| Assets | 2.90 | 4.84 | 6.09 | 5.14 | 4.00 | 0.88 | 1.59 | 0.02 | 0.02 |
| Liabilities | 3.71 | 3.48 | 3.86 | 1.98 | 2.46 | 7.77 | 1.40 | 2.79 | - |
| Book Value | -0.81 | 1.36 | 2.23 | 3.16 | 1.54 | -6.89 | 0.19 | -2.77 | 0.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arch Therapeutics, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
Terrence W. Norchi |
Stock Information
| Ticker Symbol |
ARTH |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ARTH |
Description
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.